SuperworthBriaCell Therapeutics EPS BCTX
Diluted earnings per share by quarter and over the last twelve months, from 2021.
- Last 12 months, to Apr 30, 2026
- n/m
- a quarter missing
- Latest quarter, Q3 FY26
- −$0.99
- Fiscal year 2024
- −$177.30
BriaCell Therapeutics' twelve-month earnings per share can't be added up yet: a quarter of its results is missing from our data.
In its latest quarter, Q3 FY26, it was −$0.99.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2024 | −$177.30 | n/a |
| FY2023 | −$196.50 | n/a |
| FY2022 | −$421.50 | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q3 FY26 | −$0.99 | n/a | n/a | |
| Q2 FY26 | −$2.58 | n/a | n/a | |
| Q1 FY26 | −$4.35 | n/a | n/a | |
| Q3 FY25 | −$16.42 | −202% | −$84.40 | |
| Q2 FY25 | −$23.31 | n/a | −$51.88 | |
| Q1 FY25 | −$32.67 | n/a | −$134.97 | |
| Q4 FY24 | −$12.00 | n/a | −$177.30 | |
| Q3 FY24 | $16.10 | n/a | −$187.80 | |
| Q2 FY24 | −$106.40 | n/a | −$251.90 | |
| Q1 FY24 | −$75.00 | n/a | −$261.00 | |
| Q4 FY23 | −$22.50 | n/a | −$196.50 | |
| Q3 FY23 | −$48.00 | n/a | −$178.50 |
Against its peers
Companies in Drug Manufacturers - General nearest BriaCell Therapeutics' size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| BCTXBriaCell Therapeutics | n/m | |
| ATNMActinium Pharmaceuticals | $0.36 | |
| SPROSpero Therapeutics | $0.11 | |
| LFVNLifevantage | $0.40 | −46% a year |
| NATRNatures Sunshine Products | $1.01 | +36% a year |
| Peer median | $0.38 |
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on BriaCell Therapeutics
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.